Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RICE: Durvalumab and Tremelimumab in Esophageal Adenocarcinoma
NCT04159974Phase 2Unknown
- Sponsor
- University of Cologne
- Start
- Sep 2019
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Cologne. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04159974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159974.